Advertisement
Advertisement

GRAL

GRAL logo

GRAIL, Inc. Common Stock

51.71
USD
Sponsored
+2.24
+4.53%
Apr 17, 16:00 UTC -4
Closed
exchange

After-Market

51.59

-0.13
-0.24%

GRAL Earnings Reports

Positive Surprise Ratio

GRAL beat 5 of 5 last estimates.

100%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$39.66M
/
-$2.81
Implied change from Q4 25 (Revenue/ EPS)
-9.03%
/
+15.16%
Implied change from Q1 25 (Revenue/ EPS)
+24.57%
/
-9.35%

GRAIL, Inc. Common Stock earnings per share and revenue

On Feb 19, 2026, GRAL reported earnings of -2.44 USD per share (EPS) for Q4 25, beating the estimate of -2.76 USD, resulting in a 11.60% surprise. Revenue reached 43.60 million, compared to an expected 44.55 million, with a -2.15% difference. The market reacted with a -50.55% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -2.81 USD, with revenue projected to reach 39.66 million USD, implying an increase of 15.16% EPS, and decrease of -9.03% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
For Q4 2025, GRAIL, Inc. Common Stock reported EPS of -$2.44, beating estimates by 11.6%, and revenue of $43.60M, -2.15% below expectations.
The stock price moved down -50.55%, changed from $101.53 before the earnings release to $50.21 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 6 analysts, GRAIL, Inc. Common Stock is expected to report EPS of -$2.81 and revenue of $39.66M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement